The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more.
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more.
